RX 0301
Alternative Names: HC-0301; RX-0301; WGI-0301Latest Information Update: 18 Sep 2025
At a glance
- Originator Rexahn Pharmaceuticals
- Developer Rexahn Pharmaceuticals; Zhejiang Haichang Biotechnology
- Class Antineoplastics; Antisense oligonucleotides
- Mechanism of Action Proto-oncogene protein c-akt inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical Liver cancer
- Discontinued Ovarian cancer; Pancreatic cancer; Renal cell carcinoma
Most Recent Events
- 18 Sep 2025 RX 0301 is still in phase-I clinical trials in Solid tumours(Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater, Late-stage disease) in USA (IV) (NCT05267899)
- 22 Oct 2024 Ocuphire Pharma has merged with Opus Genetics to form Opus Genetics
- 05 Apr 2024 Preclinical trials in Liver cancer in China (unspecified route) prior to April 2024